Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
Epistemonikos ID: 53889c9a86c233bae583e3efb672cd3fbf6965b3
First added on: May 14, 2024